SG11201703332SA - Binding molecules specific for cd73 and uses thereof - Google Patents

Binding molecules specific for cd73 and uses thereof

Info

Publication number
SG11201703332SA
SG11201703332SA SG11201703332SA SG11201703332SA SG11201703332SA SG 11201703332S A SG11201703332S A SG 11201703332SA SG 11201703332S A SG11201703332S A SG 11201703332SA SG 11201703332S A SG11201703332S A SG 11201703332SA SG 11201703332S A SG11201703332S A SG 11201703332SA
Authority
SG
Singapore
Prior art keywords
binding molecules
molecules specific
specific
binding
molecules
Prior art date
Application number
SG11201703332SA
Inventor
Ralph Minter
Steven Rust
Sandrine Guillard
Lutz U Jermutus
Carl Hay
Kris Sachsenmeier
Erin Sult
Qihui Huang
Peter Pavlik
Melissa Damschroder
Li Cheng
Gundo Diedrich
Jonathan Rios-Doria
Scott Hammond
Robert E Hollingsworth
Nicholas Durham
Ching Ching Leow
Mary Antonysamy
James Geoghegan
Xiaojun Lu
Kim Rosenthal
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54478033&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201703332S(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of SG11201703332SA publication Critical patent/SG11201703332SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
SG11201703332SA 2014-11-10 2015-11-09 Binding molecules specific for cd73 and uses thereof SG11201703332SA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462077486P 2014-11-10 2014-11-10
US201562147329P 2015-04-14 2015-04-14
US201562188999P 2015-07-06 2015-07-06
PCT/EP2015/076111 WO2016075099A1 (en) 2014-11-10 2015-11-09 Binding molecules specific for cd73 and uses thereof

Publications (1)

Publication Number Publication Date
SG11201703332SA true SG11201703332SA (en) 2017-05-30

Family

ID=54478033

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201703332SA SG11201703332SA (en) 2014-11-10 2015-11-09 Binding molecules specific for cd73 and uses thereof

Country Status (27)

Country Link
US (5) US9938356B2 (en)
EP (2) EP3218406B1 (en)
JP (3) JP6755866B2 (en)
KR (1) KR20170080607A (en)
CN (2) CN107001472B (en)
AU (1) AU2015345202B2 (en)
BR (1) BR112017009398A2 (en)
CA (1) CA2967118A1 (en)
CL (2) CL2017001154A1 (en)
CY (1) CY1124791T1 (en)
DK (1) DK3218406T3 (en)
ES (1) ES2877080T3 (en)
GB (1) GB2537445A (en)
HR (1) HRP20210888T1 (en)
HU (1) HUE054339T2 (en)
IL (1) IL251891B (en)
LT (1) LT3218406T (en)
MX (1) MX2017005976A (en)
MY (1) MY191423A (en)
PL (1) PL3218406T3 (en)
PT (1) PT3218406T (en)
RS (1) RS62003B1 (en)
RU (1) RU2730665C2 (en)
SG (1) SG11201703332SA (en)
SI (1) SI3218406T1 (en)
TW (1) TWI710576B (en)
WO (1) WO2016075099A1 (en)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS59480B1 (en) 2013-12-12 2019-12-31 Shanghai hengrui pharmaceutical co ltd Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
EP3142751B1 (en) * 2014-05-13 2019-08-07 MedImmune Limited Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small cell lung cancer
AU2015345202B2 (en) * 2014-11-10 2021-05-13 Medimmune Limited Binding molecules specific for CD73 and uses thereof
JP6847037B2 (en) * 2014-11-11 2021-03-24 メディミューン リミテッド Concomitant therapeutic agents containing anti-CD73 antibody and A2A receptor inhibitor and their use
RS60631B1 (en) 2014-11-21 2020-09-30 Bristol Myers Squibb Co Antibodies against cd73 and uses thereof
EP3221346B1 (en) 2014-11-21 2020-09-02 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
EP3362475B1 (en) 2015-10-12 2023-08-30 Innate Pharma Cd73 blocking agents
EA201891983A8 (en) 2016-03-04 2020-05-28 Бристол-Майерс Сквибб Компани COMBINED THERAPY BY ANTIBODIES TO CD73
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
LT3463435T (en) 2016-06-02 2021-12-27 Medimmune Limited Antibodies to alpha-synuclein and uses thereof
TWI784957B (en) 2016-06-20 2022-12-01 英商克馬伯有限公司 Immunocytokines
CN109476755B (en) * 2017-01-24 2020-12-04 天境生物科技(上海)有限公司 CD73 antibodies and uses thereof
CN110382544B (en) 2017-03-16 2023-12-22 先天制药公司 Compositions and methods for treating cancer
EP3606962A4 (en) * 2017-04-04 2020-12-23 Corvus Pharmaceuticals, Inc. Methods for treating cd73hi tumors
KR102376863B1 (en) 2017-05-12 2022-03-21 하푼 테라퓨틱스, 인크. mesothelin binding protein
JP7366755B2 (en) 2017-05-30 2023-10-23 ザ ボード オブ リージェンツ オブ ザ ユニヴァーシティ オブ オクラホマ Anti-doublecortin-like kinase 1 antibody and usage method
JP7433910B2 (en) * 2017-06-22 2024-02-20 ノバルティス アーゲー Antibody molecules against CD73 and uses thereof
WO2018237173A1 (en) * 2017-06-22 2018-12-27 Novartis Ag Antibody molecules to cd73 and uses thereof
EP3658143A4 (en) 2017-07-26 2021-04-21 Chong Kun Dang Pharmaceutical Corp. Composition for preventing or treating cancer comprising a vascular disrupting agent and immune checkpoint inhibitor
SG11202002192QA (en) 2017-10-06 2020-04-29 Innate Pharma Restoration of t cell activity via the cd39/cd73 axis
KR20200096253A (en) 2017-11-30 2020-08-11 노파르티스 아게 BCMA-targeting chimeric antigen receptor, and uses thereof
JP7409669B2 (en) * 2017-12-04 2024-01-09 ザ ボード オブ リージェンツ オブ ザ ユニバーシティ オブ オクラホマ Anti-DCLK1 antibodies and chimeric antigen receptors, and compositions and methods of use thereof
PE20211001A1 (en) 2018-02-27 2021-06-01 Incyte Corp IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS INHIBITORS OF A2A / A2B
WO2019170131A1 (en) 2018-03-07 2019-09-12 复旦大学 Targeted cd73 antibody and antibody-drug conjugate, and preparation method therefor and uses thereof
CN110240654A (en) * 2018-03-07 2019-09-17 复旦大学 In conjunction with the antibody-drug conjugates of CD73
CR20200392A (en) * 2018-03-09 2020-11-17 Agenus Inc Anti-cd73 antibodies and methods of use thereof
CN111867628A (en) * 2018-03-09 2020-10-30 东莞凡恩世生物医药有限公司 anti-CD 73 antibodies and uses thereof
CA3096674A1 (en) 2018-04-12 2019-10-17 Bristol-Myers Squibb Company Anticancer combination therapy with cd73 antagonist antibody and pd-1/pd-l1 axis antagonist antibody
JP7391046B2 (en) 2018-05-18 2023-12-04 インサイト・コーポレイション Fused pyrimidine derivatives as A2A/A2B inhibitors
EP3569618A1 (en) 2018-05-19 2019-11-20 Boehringer Ingelheim International GmbH Antagonizing cd73 antibody
TW202015726A (en) 2018-05-30 2020-05-01 瑞士商諾華公司 Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
AU2019277029C1 (en) 2018-06-01 2024-01-04 Novartis Ag Binding molecules against BCMA and uses thereof
EA202092518A1 (en) 2018-06-18 2021-08-23 Иннейт Фарма COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER
CN112041348B (en) 2018-07-25 2023-09-22 天境生物科技(上海)有限公司 anti-CD 73 anti-PD-L1 bispecific antibodies
JP7425049B2 (en) 2018-09-25 2024-01-30 ハープーン セラピューティクス，インク． DLL3 binding protein and method of use
KR20210093255A (en) * 2018-11-12 2021-07-27 지앙수 헨그루이 메디슨 컴퍼니 리미티드 Anti-CD73 antibodies, antigen-binding fragments thereof and applications thereof
CN111499747B (en) * 2019-01-11 2022-03-18 康诺亚生物医药科技（成都）有限公司 anti-CD 73 monoclonal antibody and application thereof
CN111434688A (en) * 2019-01-11 2020-07-21 上海开拓者生物医药有限公司 CD73 antibody and preparation method and application thereof
TWI829857B (en) 2019-01-29 2024-01-21 美商英塞特公司 Pyrazolopyridines and triazolopyridines as a2a / a2b inhibitors
CN113795267A (en) * 2019-03-12 2021-12-14 艾库斯生物科学有限公司 Oncogene driven treatment of cancer
CA3134671A1 (en) * 2019-04-02 2020-10-08 Medimmune, Llc Anti-cd73, anti-pd-l1 antibodies and chemotherapy for treating tumors
WO2020253568A1 (en) * 2019-06-19 2020-12-24 海正生物制药有限公司 Anti-cd73 antibody and application thereof
CN112300279A (en) * 2019-07-26 2021-02-02 上海复宏汉霖生物技术股份有限公司 Methods and compositions directed to anti-CD 73 antibodies and variants
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
CN113454121B (en) * 2019-08-21 2022-03-08 和铂医药(上海)有限责任公司 anti-CD 73 antibodies and uses thereof
MX2022002324A (en) * 2019-08-30 2022-04-06 Genentech Inc Developing an efficient hybridoma platform for therapeutic antibody discovery.
EP4025605A1 (en) 2019-09-06 2022-07-13 Symphogen A/S Anti-cd73 antibodies
JP2022548881A (en) 2019-09-18 2022-11-22 ノバルティス アーゲー ENTPD2 Antibodies, Combination Therapy and Methods of Using Antibodies and Combination Therapy
WO2021097223A2 (en) * 2019-11-15 2021-05-20 Genzyme Corporation Biparatopic cd73 antibodies
US20210230294A1 (en) 2020-01-03 2021-07-29 Incyte Corporation Cd73 inhibitor and a2a/a2b adenosine receptor inhibitor combination therapy
CA3166533A1 (en) * 2020-01-03 2021-07-08 Incyte Corporation Anti-cd73 antibodies and uses thereof
JP2023522730A (en) * 2020-04-22 2023-05-31 アケソ・バイオファーマ・インコーポレイテッド Anti-CD73/anti-PD-1 bispecific antibodies and uses thereof
WO2021241729A1 (en) 2020-05-29 2021-12-02 ブライトパス・バイオ株式会社 Anti-cd73 antibody and use thereof
WO2021247188A1 (en) 2020-06-05 2021-12-09 Bristol-Myers Squibb Company Cd73 antagonist potency assay and methods of use thereof
CN111714642A (en) * 2020-06-18 2020-09-29 复旦大学 Application of CD73 antibody-drug conjugate
JP2023532234A (en) 2020-06-22 2023-07-27 イノベント バイオロジクス（スーチョウ）カンパニー，リミティド Anti-CD73 antibody and its use
CA3182579A1 (en) 2020-07-07 2022-01-13 Ugur Sahin Therapeutic rna for hpv-positive cancer
WO2022037531A1 (en) * 2020-08-17 2022-02-24 中山康方生物医药有限公司 Anti-cd73 antibody and use thereof
CN114380915B (en) * 2020-10-19 2024-03-22 中山康方生物医药有限公司 anti-CD 73 antibodies and uses thereof
WO2022083723A1 (en) * 2020-10-23 2022-04-28 中山康方生物医药有限公司 Anti-cd73 antibody and use thereof
WO2022097060A1 (en) 2020-11-06 2022-05-12 Novartis Ag Cd19 binding molecules and uses thereof
CN117164713A (en) * 2020-11-09 2023-12-05 江苏中新医药有限公司 Anti-extracellular-5' -nucleotidase antibody and application thereof in preparing tumor drugs
TW202222840A (en) * 2020-12-11 2022-06-16 大陸商上海華奧泰生物藥業股份有限公司 Cd73 antigen binding protein and the application thereof
TW202245808A (en) 2020-12-21 2022-12-01 德商拜恩迪克公司 Therapeutic rna for treating cancer
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
CA3207066A1 (en) * 2020-12-29 2022-07-07 Incyte Corporation Combination therapy comprising a2a/a2b inhibitors, pd-1/pd-l1 inhibitors, and anti-cd73 antibodies
CN113061177B (en) * 2020-12-31 2022-07-01 浙江大学 CD73 enzyme activity related antigen epitope and preparation method of specific antibody aiming at epitope
CN113045659B (en) * 2021-03-18 2022-03-18 上海近岸科技有限公司 anti-CD73 humanized antibodies
GB202105110D0 (en) * 2021-04-09 2021-05-26 Cancer Research Tech Ltd Anti-CD73 antibodies
EP4349867A1 (en) * 2021-05-28 2024-04-10 Harbour Biomed (Shanghai) Co., Ltd Specific binding protein targeting pd-l1 and cd73
AU2022312698A1 (en) 2021-07-13 2024-01-25 BioNTech SE Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
TW202333802A (en) 2021-10-11 2023-09-01 德商拜恩迪克公司 Therapeutic rna for lung cancer
WO2023174213A1 (en) * 2022-03-14 2023-09-21 上海华奥泰生物药业股份有限公司 Antibody-drug conjugate and use thereof
WO2023201267A1 (en) 2022-04-13 2023-10-19 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
CN117304316A (en) * 2022-06-22 2023-12-29 复旦大学 CD 73-targeting nanobody, nanobody-drug conjugate, preparation method and application thereof
CN115991772B (en) * 2022-08-12 2023-09-01 南京蓬勃生物科技有限公司 anti-CD 73 antibody or antigen fragment thereof and application thereof
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US6492107B1 (en) 1986-11-20 2002-12-10 Stuart Kauffman Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
EP0229046B1 (en) 1985-03-30 1994-05-04 BALLIVET, Marc Method for obtaining dna, rna, peptides, polypeptides or proteins by means of a dna recombinant technique
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
DE3600905A1 (en) 1986-01-15 1987-07-16 Ant Nachrichtentech METHOD FOR DECODING BINARY SIGNALS AND VITERBI DECODERS AND APPLICATIONS
US5681718A (en) 1986-03-14 1997-10-28 Celltech Limited Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2016841C (en) 1989-05-16 1999-09-21 William D. Huse A method for producing polymers having a preselected activity
WO1990014443A1 (en) 1989-05-16 1990-11-29 Huse William D Co-expression of heteromeric receptors
CA2016842A1 (en) 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ES2246502T3 (en) 1990-08-29 2006-02-16 Genpharm International, Inc. TRANSGENIC NON-HUMAN ANIMALS ABLE TO PRODUCE HETEROLOGICAL ANTIBODIES.
ES2113940T3 (en) 1990-12-03 1998-05-16 Genentech Inc ENRICHMENT METHOD FOR PROTEIN VARIANTS WITH ALTERED UNION PROPERTIES.
DE69131017T2 (en) 1990-12-20 1999-07-15 Ixsys Inc OPTIMIZATION OF BINDING PROTEINS
DK1024191T3 (en) 1991-12-02 2008-12-08 Medical Res Council Preparation of autoantibodies displayed on phage surfaces from antibody segment libraries
ES2202310T3 (en) 1991-12-13 2004-04-01 Xoma Corporation METHODS AND MATERIALS FOR THE PREPARATION OF VARIABLE DOMAINS OF MODIFIED ANTIBODIES AND THEIR THERAPEUTIC USES.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US7264963B1 (en) 1995-08-18 2007-09-04 Morphosys Ag Protein(poly)peptide libraries
EP0859841B1 (en) 1995-08-18 2002-06-19 MorphoSys AG Protein/(poly)peptide libraries
US6331431B1 (en) 1995-11-28 2001-12-18 Ixsys, Inc. Vacuum device and method for isolating periplasmic fraction from cells
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
WO2001002588A2 (en) 1999-07-02 2001-01-11 Morphosys Ag Generation of specific binding partners binding to (poly)peptides encoded by genomic dna fragments or ests
KR20020091170A (en) * 2000-03-31 2002-12-05 아이덱 파마슈티칼즈 코포레이션 Combined use of anti-cytokine antibodies or antagonists and anti-cd20 for the treatment of b cell lymphoma
EP2341060B1 (en) 2000-12-12 2019-02-20 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
US7538195B2 (en) 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
MXPA05004712A (en) 2002-11-07 2005-11-23 Immunogen Inc Anti-cd33 antibodies and method for treatment of acute myeloid leukemia using the same.
US7158164B2 (en) 2003-08-29 2007-01-02 Fuji Photo Film Co., Ltd. Thermal development method and apparatus
WO2005075514A2 (en) 2004-03-10 2005-08-18 Lonza Ltd. Method for producing antibodies
WO2006024497A1 (en) 2004-08-30 2006-03-09 Lonza Biologics Plc. Affinity- plus ion exchange- chromatography for purifying antibodies
JP5382692B2 (en) 2006-07-10 2014-01-08 学校法人藤田学園 Antibody classification method, antigen identification method, antibody or antibody set acquisition method, antibody panel preparation method, and antibody or antibody set and use thereof
US20100003189A1 (en) * 2006-07-14 2010-01-07 The Regents Of The University Of California Cancer biomarkers and methods of use thereof
US7691980B2 (en) 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
EP2287174B8 (en) 2008-01-18 2016-12-07 Bio-Rad Laboratories, Inc. Enhanced purification of antibody fragments by apatite chromatography
JP5470817B2 (en) 2008-03-10 2014-04-16 日産自動車株式会社 Battery electrode, battery using the same, and manufacturing method thereof
ES2602459T3 (en) * 2008-12-26 2017-02-21 Kyowa Hakko Kirin Co., Ltd. Anti-CD4 antibody
NZ599405A (en) 2009-11-24 2014-09-26 Medimmune Ltd Targeted binding agents against b7-h1
WO2011066501A1 (en) 2009-11-30 2011-06-03 Centocor Ortho Biotech Inc. Antibody fc mutants with ablated effector functions
WO2011120135A1 (en) 2010-03-29 2011-10-06 Zymeworks, Inc. Antibodies with enhanced or suppressed effector function
BR112012026227A2 (en) * 2010-04-13 2020-08-04 Celldex Therapeutics, Inc. human or humanized monoclonal antibody, bispecific molecule, expression vector, transformed cell, composition, and, uses of an antibody
EP2576616A4 (en) 2010-05-27 2014-05-21 Merck Sharp & Dohme Method for preparing antibodies having improved properties
EP2537864B1 (en) 2011-06-24 2019-08-07 Laboratoire Français du Fractionnement et des Biotechnologies Fc variants with reduced effector functions
RU2019133467A (en) 2011-10-11 2020-07-06 МЕДИММЬЮН, ЭлЭлСи CD40L-SPECIFIC FRAME STRUCTURES ORIGINING FROM TN3, AND METHODS OF APPLICATION
WO2014153424A1 (en) 2013-03-19 2014-09-25 La Jolla Institute For Allergy And Immunology Reducing diabetes in patients receiving hmg-coa reductase inhibitors (statins)
TWI503850B (en) 2013-03-22 2015-10-11 Polytronics Technology Corp Over-current protection device
US10766966B2 (en) 2014-10-10 2020-09-08 Innate Pharma CD73 blockade
AU2015345202B2 (en) * 2014-11-10 2021-05-13 Medimmune Limited Binding molecules specific for CD73 and uses thereof
RS60631B1 (en) 2014-11-21 2020-09-30 Bristol Myers Squibb Co Antibodies against cd73 and uses thereof
US9816280B1 (en) 2016-11-02 2017-11-14 Matthew Reitnauer Portable floor

Also Published As

Publication number Publication date
US10556968B2 (en) 2020-02-11
RU2017117596A (en) 2018-12-17
TWI710576B (en) 2020-11-21
IL251891A0 (en) 2017-06-29
EP3901176A1 (en) 2021-10-27
US20160194407A1 (en) 2016-07-07
IL251891B (en) 2021-03-25
HRP20210888T1 (en) 2021-07-23
US20230340152A1 (en) 2023-10-26
US9938356B2 (en) 2018-04-10
GB2537445A (en) 2016-10-19
JP2022115962A (en) 2022-08-09
US10287362B2 (en) 2019-05-14
SI3218406T1 (en) 2021-08-31
PL3218406T3 (en) 2021-10-04
CA2967118A1 (en) 2016-05-19
KR20170080607A (en) 2017-07-10
HUE054339T2 (en) 2021-08-30
RU2730665C2 (en) 2020-08-24
RS62003B1 (en) 2021-07-30
JP2018501197A (en) 2018-01-18
CL2017001154A1 (en) 2018-01-12
CY1124791T1 (en) 2022-11-25
US20180194858A1 (en) 2018-07-12
TW201632555A (en) 2016-09-16
MY191423A (en) 2022-06-27
CL2020003409A1 (en) 2021-07-02
ES2877080T3 (en) 2021-11-16
CN107001472A (en) 2017-08-01
EP3218406B1 (en) 2021-03-24
JP7069261B2 (en) 2022-05-17
JP2020195394A (en) 2020-12-10
MX2017005976A (en) 2017-06-29
PT3218406T (en) 2021-06-17
DK3218406T3 (en) 2021-06-21
EP3218406A1 (en) 2017-09-20
US20200079877A1 (en) 2020-03-12
WO2016075099A1 (en) 2016-05-19
AU2015345202A1 (en) 2017-05-18
US11525012B2 (en) 2022-12-13
CN107001472B (en) 2020-12-11
GB201519761D0 (en) 2015-12-23
CN112778418A (en) 2021-05-11
LT3218406T (en) 2021-06-25
RU2017117596A3 (en) 2019-06-17
AU2015345202B2 (en) 2021-05-13
BR112017009398A2 (en) 2018-05-15
US20190292274A1 (en) 2019-09-26
JP6755866B2 (en) 2020-09-16

Similar Documents

Publication Publication Date Title
IL251891B (en) Binding molecules specific for cd73 and uses thereof
IL283965A (en) Antibodies against cd73 and uses thereof
ZA201702173B (en) Sorbent for binding metal and production thereof
GB201612520D0 (en) Binding molecules
IL273641B (en) Binding molecules specific for il-21 and uses thereof
IL250796B (en) Binding proteins specific for lox1 and uses thereof
HK1258317A1 (en) Binding molecules specific for asct2 and uses thereof
EP3180027A4 (en) Rspo1 binding agents and uses thereof
GB201508729D0 (en) Binding molecules